Pneumonitis, a common adverse event of cyclin-dependent kinase 4/6 inhibitors: a case report

Fernanda E. Rivera-Sánchez; Carolina Moreno-Licea; Raúl Mellado-Orellana; Salvador González-Santiesteban; Roberto de la Peña-López

doi:10.18203/issn.2454-2156.IntJSciRep20220401

Authors

Fernanda E. Rivera-Sánchez Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Carolina Moreno-Licea Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Raúl Mellado-Orellana Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Salvador González-Santiesteban Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Roberto de la Peña-López Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20220401

Keywords:

CDK 4/6 inhibitors, Breast cancer, Pulmonary toxicity, Common adverse event

Abstract

The cyclin-dependent kinase (CDK) 4/6 inhibitors are approved for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, these can develop common adverse events. We present the case of a woman diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer, who developed pneumonitis related to palbociclib. Pulmonary toxicity of CDK 4/6 inhibitors is not an uncommon adverse event that has been increasing in incidence.

Metrics

Metrics Loading ...

References

Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166(1):41-54.

Wilgus M, Rosenberg J. CDK4/6 Inhibitor-Induced Pneumonitis: A Case Report and Review of the Literature. UCLA Health. 2020;24.

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558-72.

Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326.

Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin dependent kinase 4/6 inhibitors. Front Pharmacol. 2019;10:1235.

Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommenda-tions. Oncologist. 2017;22(9):1039-48.

Ahsan I, Malik F, Jafri SI: Palbociclib related pnemotoxicity: a rare side effect. Am J Respir Crit Care Med. 2017;195:A5546.

Azhar A, Zaman K, Samad R. A tale of unexplained pneumotoxicity: the dangers of palbociclib. Am J Respir Crit Care Med. 2020;201:A3120.

Felip E, Llobera L, Perez-Mañá C. New drugs, old toxicities: pneumonitis related to palbociclib-a case report [Epub ahead of print]. Breast Care. 2019;10:1159/000504618.

Gong J, Cho M, Yu KW, Waisman J, Yuan Y, Mortimer J. A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 2018;168(2):381-7.

Jazieh KA, Budd GT, Dalpiaz N, Abraham J. Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 2019;19(11):917-9.

Levy O, Ptashkin E, Shechtman Y, Tamar K, Natif N, Sanset S, Katz D. Fatal Palbociclib related interstitial pneumonitis. Arch Clin Med Case Rep. 2019;3:162-6.

Okura F, Sato Y, Murakami E, Komatsu H, Yamamura Y, Ito Y. A case of interstitial pneumonitis induced by palbociclib. (Article in Japanese). Gan To Kagaku Ryoho. 2020;47:997-9.

Birnhuber A, Egemnazarov B, Biasin V. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin induced lung fibrosis. Respiratory res. 2020;21(1):167.

Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219-27.

U.S. Food and Drug Administration. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer: FDA Drug Safety Communication. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed on 2 August 2021.

Johnston S, Martin M, Di Leo A. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5:5.

Sledge GW, Toi M, Neven P. Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-84.

Hortobagyi GN, Stemmer SM, Burris HA. Updated results from MONALEESA-2, a phase III trial of first line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-7.

Loibl S, Turner NC, Ro J. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist. 2017;22(9):1028-38.